Suggestions
Manijeh Goldberg, PhD
CEO Privo Technologies, Harvard Medical School, MIT
Manijeh Goldberg, PhD, is a prominent figure in the biomedical industry with extensive experience in both large companies and startups. She is the Founder and CEO of Privo Technologies, an innovative oncology company focused on transforming oral cancer therapy.16
Dr. Goldberg has over 20 years of experience in the biomedical field and has been involved in five startups, one of which was acquired for $475 million.1 Her current work at Privo Technologies involves developing nano-engineered technology, about the size of a penny, that delivers anti-cancer agents directly to oral and other cancers.2
Education and Expertise
Manijeh Goldberg holds an impressive array of academic credentials:
- PhD in Biomedical Engineering
- MS in Health Sciences and Technology from Harvard Medical School
- MBA from MIT Sloan School of Management
- MS in Computer Science and Mathematics1
Professional Roles
In addition to her role as CEO of Privo Technologies, Dr. Goldberg has served in various capacities:
- Scientific Reviewer at the National Cancer Institute (NCI)
- Mentor to medical students, scientists, and engineers at Harvard Medical School3
- Principal Investigator in research projects
Research and Innovation
Dr. Goldberg's work has contributed significantly to the field of oncology. She has developed key opinion leader relationships in the US and successfully lobbied to include PRV111 (one of Privo's products) in a large, NIH-funded clinical study.1 Her research focuses on innovative cancer treatments that are "tough on cancer, easy on patients".4
At Privo Technologies, Dr. Goldberg is driving the execution of second-generation products, conducting clinical trials, and working towards FDA approval for PRV111. Her responsibilities also include business development and general management.1
Dr. Goldberg's research has been cited in scientific literature, with contributions to studies on polymeric nanoparticle suspensions for cancer treatment.5